Bristol Myers Squibb Names New GC as Legal Chief Retires
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
Bristol Myers Squibb GC to Retire After 33 years With Drugmaker
Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...
GlobalData on MSN3d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Bristol Myers reports no new safety signals observed in five-year Sotyktu data
Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients ...
PMLiVE2d
Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis
Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 ...
The Pharma Letter6d
Bristol Myers’ Phase III Opdualag trial misses goal
Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...
Pharmabiz2d
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...
Le Lézard4d
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...
Monthly Prescribing Reference6d
Nivolumab/Relatlimab Combo Fails to Meet RFS Endpoint in Melanoma Trial
Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.
pharmaphorum1d
A history of Bristol-Myers Squibb
Frederic N. Schwartz became president and CEO of Bristol-Myers when Henry Bristol chose to give up some of his responsibilities as he approached the age of 70. "In 1955, Squibb received one of the ...
Irish Examiner on MSN6d
New investments show Ireland still first port of call for US firms
Business Editor Alan Healy reports on Ireland's enduring appeal as a location for US firms to set up shop — despite a ...